A success – and a pretty good one. New data on Opdivo revealed in a late-breaking abstract released early at this weekend’s European Society for Medical Oncology (ESMO) meeting in Madrid, suggests that Bristol Myers Squibb Company’s checkpoint inhibitor might be a serious rival to Merck & Co., Inc.’s powerhouse Keytruda.
Key Takeaways
- Opdivo cuts the risk of progression, recurrence or death by 42% when used perioperatively for non-small cell lung cancer
- This is the exact same benefit Keytruda showed in its comparable trial
- But Keytruda reached market first and Bristol will
The setting is perioperative non-small cell lung cancer (NSCLC), in which a drug, plus chemotherapy, is given both before and after tumor resection. Keytruda (pembrolizumab) was approved for this use just this week, and now it looks highly probable that Opdivo (nivolumab) will join it
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
